12 completed, 1 not yet recruiting, 1 terminated. 5 Phase 1, 5 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 5 | Completed 5 |
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
Follow Dyslipidaemias: new trials by email Literature Review of Dyslipidaemias trials Research Report on Dyslipidaemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy of a Food Supplement Consisting of the Combination of an Olive Extract and a Myrtle Extract for the Improvement of Lipid Metabolism in Subjects With Slightly Altered Cholesterolemia Values Food supplement (T1675), Placebo - Dyslipidaemias | Not applicable | Completed | Labomar SPA | 112 | 2026-03-09 | 2026-06-25 |
| Improved Medication and Care to Achieve Lipid Targets After Carotid Surgery Prompt Medication Adjustment and Intensive Follow-up, Standard Care - Dyslipidaemias, Carotid Artery Stenoses | Not applicable | Not yet recruiting | Barmherzige Brüder Linz | 50 | 2025-08-04 | 2025-08-07 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin 10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo - Dyslipidaemias, Dyslipidemias | Phase 2 | Completed | GlaxoSmithKline | 287 | 2010-09-14 | 2019-07-16 |
| Study to Test GSK256073 in Patients With Dyslipidemia GSK256073, Placebo, Niaspan - Dyslipidaemias, Dyslipidemias | Phase 2 | Completed | GlaxoSmithKline | 80 | 2009-06-15 | 2019-12-05 |
| A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs. an undetermined dose of GSK1292263, ascending dose of GSK1292263 - Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 76 | 2008-09-04 | 2017-07-07 |
| Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects GSK256073 - Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 30 | 2008-05-12 | 2017-06-05 |
| A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers GSK256073A tablets + IR niacin tablets - Healthy Subjects, Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 24 | 2007-12-01 | 2012-04-30 |
| A Second Study to Determine the Effect of GSK256073A on HVTs GSK256073A tablets - Healthy Subjects, Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 4 | 2007-10-01 | 2012-06-04 |
| Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia. GW856553 - Healthy Subjects, Dyslipidaemias | Phase 2 | Completed | GlaxoSmithKline | 66 | 2007-07-01 | 2012-06-06 |
| Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers GSK256073A tablets - Healthy Subjects, Dyslipidaemias | Phase 1 | Completed | GlaxoSmithKline | 56 | 2007-06-01 | 2012-06-04 |
| Effect Of GW501516X On How The Heart Obtains And Uses Energy GW510516X - Dyslipidaemias, Heart Failure | Terminated | GlaxoSmithKline | 30 | 2005-12-01 | 2012-03-19 | |
| An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation GW501516, GW590735 - Hypercholesterolemia, Dyslipidaemias | Completed | GlaxoSmithKline | 71 | 2004-12-01 | 2012-03-19 | |
| GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol GW501516 oral tablets - Dyslipidaemias, Dyslipidaemia | Phase 2 | Completed | GlaxoSmithKline | 424 | 2004-08-01 | 2017-05-30 |
| Dyslipidemia Study Investigating The Increase In "Good Cholesterol" GW590735, fenofibrate - Dyslipidaemias | Phase 2 | Completed | GlaxoSmithKline | 250 | 2003-11-01 | 2012-10-22 |
Dyslipidemias (5) · Atherosclerosis (1) · Carotid Stenosis (1) · Flushing (1) · Heart Failure (1) · Hypercholesterolemia (1) · Hypertriglyceridemia (1) · Inflammation (1) · Obesity (1) · Platelet Glycoprotein IV Deficiency (1)
Lipid Metabolism Disorders (7) · Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Cardiovascular Diseases (3) · Arterial Occlusive Diseases (2) · Dyslipidemias (2) · Hyperlipidemias (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Vascular Diseases (2) · Arteriosclerosis (1) · Body Weight (1) · Brain Diseases (1) · Carotid Artery Diseases (1) · Central Nervous System Diseases (1)
2-methyl-2-(4-(((4-methyl-2-(4-trifluoromethylphenyl)-thiazol-5-ylcarbonyl)amino)methyl)phenoxy)propionic acid (2) · 8-chloro-3-pentyl-1H-purine-2,6(3H,7H)-dione (2) · GW 501516 (2) · (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate (1) · 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide (1) · Atorvastatin (1) · Dietary Supplements (1) · Ezetimibe (1) · Fenofibrate (1) · Niacin (1) · Standard of Care (1) · WASH protein, Drosophila (1)
GlaxoSmithKline (12) · Barmherzige Brüder Linz (1) · Labomar SPA (1)
United States (10) · Austria (1) · Belgium (1) · Canada (1) · Denmark (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Italy (1) · Lithuania (1) · Netherlands (1) · Norway (1) · Portugal (1) · Sweden (1)
Claudio C Polistina, graduated (1) · Juergen Falkensammer, Associate Professor, MD (1) · Martin Clodi, Professor, MD (1)